MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS
ConclusionsMiR-143-3p may suppress tumorigenesis in PDAC by targeting KRAS. This might provide a theoretical basis for miR-143-3p in treatment of pancreatic cancer.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Drugs & Pharmacology | Genetics | Pancreas | Pancreatic Cancer | Transplants